CN112194572A - Phenolic compound ZKYY-037 and preparation method and application thereof - Google Patents
Phenolic compound ZKYY-037 and preparation method and application thereof Download PDFInfo
- Publication number
- CN112194572A CN112194572A CN202011176024.4A CN202011176024A CN112194572A CN 112194572 A CN112194572 A CN 112194572A CN 202011176024 A CN202011176024 A CN 202011176024A CN 112194572 A CN112194572 A CN 112194572A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- column chromatography
- silica gel
- gel column
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
- C07C39/15—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings, e.g. phenylphenol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/004—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by obtaining phenols from plant material or from animal material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Abstract
The invention discloses a phenolic compound ZKYY-037, a preparation method and application thereof, wherein the compound has a structure shown in a formula I:
the compound can be obtained by extracting the hemp plant flowers to obtain a crude extract, and then separating the crude extract, and cell experiments show that the compound has better anti-tumor cell proliferation activity, and particularly has obvious effect of inhibiting cell proliferation in liver cancer cells and lung cancer cells.
Description
Technical Field
The invention relates to the technical field of biological medicines, and particularly relates to a phenolic compound ZKYY-037 and a preparation method and application thereof.
Background
The hemp plant is a plant with a complex chemical type, mainly because the hemp plant contains many natural chemical components. By 1980, there were 432 species of compounds isolated from hemp plants, increasing to 483 species by 1995 and 490 species by 2005. The biological activity of cannabis is well known and with the discovery of receptors, there is an opportunity to explore physiologically active compounds in cannabis as a source of new therapeutic agents. There are also an increasing number of patients suffering from severe diseases such as cancer who seek natural drugs as an alternative or complementary therapy, and there is a continuing need for new treatments for cancer or other symptoms.
The incidence rate of cancer is gradually high due to different living habits, environmental factors and other reasons, the malignant tumor is found to be a disease which is difficult to cure once being found in an advanced stage, and the cancer incidence rate is high and the cancer is difficult to cure at present, so the method has important significance for screening active ingredients in the hemp plants.
Disclosure of Invention
In view of the above, the invention provides an application of a phenolic compound ZKYY-037 with a molecular formula of C18H22O3And the molecular weight is 286.37, and the compound has good anti-tumor cell proliferation activity.
The invention provides a compound ZKYY-037, which has a structure shown in a formula I:
the invention also provides a preparation method of the compound shown in the formula I, which comprises the following steps:
(1) sequentially performing carbon dioxide supercritical extraction and ethanol extraction on the hemp plant inflorescence to obtain a crude extract;
(2) dissolving the obtained crude extract, and separating by normal phase silica gel column chromatography, macroporous adsorbent resin column chromatography, primary medium pressure normal phase silica gel column chromatography, secondary medium pressure normal phase silica gel column chromatography, tertiary medium pressure normal phase silica gel column chromatography, and high pressure reverse phase HPLC chromatography to obtain compound shown in formula I.
Preferably, the method of preparation comprises any one or more of the following features: firstly, the supercritical carbon dioxide extraction conditions are as follows: pExtraction kettle＝20-30MPa，TExtraction kettle＝35-60℃；PSeparation kettle I＝8-11MPa，TSeparation kettle I＝35-65℃；PSeparation kettle II＝3-6MPa，TSeparation kettle II30-40 ℃; secondly, the usage amount of ethanol in the ethanol extraction is 15-25% of the weight of the hemp plant inflorescence, and the extraction time is 30-60 min; thirdly, fully dissolving the crude extract by using petroleum ether; fourthly, the normal phase silica gel column chromatography is carried out with n-hexane/ethyl acetate 98:2 as an eluent for isocratic elution; fifthly, performing gradient elution on the macroporous adsorption resin column by adopting a D101 macroporous adsorption resin column and using 30-100% ethanol/water as an eluent; sixthly, performing gradient elution on the first-stage medium-pressure normal-phase silica gel column chromatography by using dichloromethane/ethyl acetate as an eluent; seventhly, performing gradient elution on the secondary medium-pressure normal-phase silica gel column chromatography by using n-hexane/diethyl ether as an eluent; eighthly, carrying out gradient elution on the three-stage medium-pressure normal-phase silica gel column chromatography by using n-hexane/diethyl ether as an eluent; and ninthly, carrying out gradient elution by using acetonitrile/water solution as an eluent by the high-pressure reversed-phase HPLC chromatography.
The invention also provides application of the compound ZKYY-037 shown in the formula I in preparation of a tumor cell proliferation inhibitor.
Correspondingly, the invention provides a tumor cell proliferation inhibitor drug which is characterized by comprising an active ingredient and pharmaceutically acceptable auxiliary materials, wherein the active ingredient comprises a compound shown in a formula I.
The invention also provides application of the compound shown in the formula I in preparing a medicament for treating tumor diseases.
Correspondingly, the invention provides an anti-tumor medicament which comprises an active ingredient and pharmaceutically acceptable auxiliary materials, wherein the active ingredient comprises a compound shown in a formula I.
Preferably, the tumor disease is liver cancer or lung cancer.
Preferably, the medicament comprises an effective dose of the compound shown in the formula I, and the preferable effective dose is 572ng per dose.
Preferably, the medicine is an oral preparation or an injection preparation, and the oral preparation is one of dripping pills, tablets, capsules, granules or oral liquid; the injection preparation is selected from injection or powder injection.
The invention has the beneficial effects that: the invention provides an anti-tumor proliferation activity of a compound ZKYY-037 and a preparation method thereof. The compound can be obtained by extracting the hemp plant flowers to obtain a crude extract and then separating the crude extract, and cell experiments show that the compound has better anti-tumor cell proliferation activity, and particularly has obvious effect of inhibiting cell proliferation in liver cancer cells and lung cancer cells.
Drawings
FIG. 1 is a graph showing the effect of compounds of formula I on the survival rate of human hepatoma cells (HepG 2);
FIG. 2 shows the effect of compounds of formula I on the survival of human lung cancer cells (A549);
FIG. 3 shows the effect of compounds of formula I on the survival of human hepatoma cells (HepG 2);
FIG. 4 shows the effect of compounds of formula I on the survival of human lung cancer cells (A549);
FIG. 5 shows a microscopic image of cell colonies after treatment of human hepatoma cells (HepG2) with a compound of formula I;
FIG. 6 shows the effect of compounds of formula I on the colony formation of human hepatoma cells (HepG 2);
FIG. 7 shows a microscopic image of a cell colony obtained after treatment of human lung cancer cells (A549) with a compound of formula I;
FIG. 8 shows the effect of compounds of formula I on colony formation of human lung cancer cells (A549);
FIG. 9 shows the effect of compounds of formula I on the mobility of human hepatoma cells (HepG 2);
FIG. 10 shows the effect of compounds of formula I on the mobility of human lung cancer cells (A549);
FIG. 11 shows compounds of formula I1H-NMR spectrum;
FIG. 12 shows a compound of formula I13C-NMR spectrum.
Detailed Description
To explain technical contents, structural features, and objects and effects of the technical solutions in detail, the following detailed description is given with reference to the accompanying drawings in conjunction with the embodiments.
The invention provides an unreported phenolic compound ZKYY-037, which has a structure shown in a formula I:
example 1
The preparation method of the phenolic compound ZKYY-037 shown in the formula I comprises the following steps:
(1) taking a hemp plant inflorescence as a raw material, crushing 500g of a dried sample, and performing supercritical extraction by using carbon dioxide. The extraction conditions were: pExtraction kettle＝30MPa，TExtraction kettle＝45℃；PSeparation kettle I＝8MPa，TSeparation kettle I＝45℃；PSeparation kettle II＝6MPa，TSeparation kettle IIThe temperature is 35 ℃; adding 20 wt% ethanol as carrier, and extracting for 45 min. Extracting to obtain 101.031g of crude extract.
(2) Fully dissolving 50g of crude extract by using petroleum ether, performing normal-phase silica gel column chromatography by using a Changzhou tritai medium-pressure rapid preparation chromatograph, performing gradient elution by using n-hexane/ethyl acetate 98:2 and the like as an eluent until the peak value of the sixth peak of online detection is lower than 100mAU and the flow rate is 80mL/min, analyzing by using thin-layer chromatography, and combining the sixth peaks of online detection maps to obtain a first-stage component containing a target compound; and (3) taking 7.8g of first-grade component, further separating by using D101 macroporous adsorption resin column chromatography, carrying out gradient elution by using 30-100% ethanol/water in an elution system, and regulating the flow rate until the eluent flows down in a strand. And (4) carrying out thin-layer chromatography analysis, and combining the elution parts of 45% ethanol solution to obtain a secondary component containing the target compound. And taking 1.62g of the secondary component, and further performing medium-pressure normal-phase silica gel column chromatography separation, wherein an elution system is a dichloromethane/ethyl acetate system for gradient elution, and the elution is carried out until the peak value of the eighth peak detected on line is lower than 50mAU, and the flow rate is 15 mL/min. And (3) carrying out thin-layer chromatography analysis, combining the first peaks of the online detection maps to obtain a third-level component containing the target compound, taking 0.732g of the third-level component, further separating by using medium-pressure normal-phase silica gel column chromatography, carrying out gradient elution by using n-hexane/diethyl ether in an elution system until the peak value of the fourteenth peak detected online is lower than 30mAU, and carrying out flow rate of 15 mL/min. And (3) carrying out thin-layer chromatography analysis, combining the ninth peak of the online detection spectrum to obtain a fourth-stage component containing the target compound, taking 0.306g of the fourth-stage component, further carrying out chromatography separation by adopting medium-pressure normal-phase silica gel, carrying out gradient elution by using n-hexane/diethyl ether as an elution system until the peak value of the third peak of online detection is lower than 30mAU, and carrying out flow rate of 15 mL/min. Performing thin-layer chromatography, combining the third peaks of the online detection maps to obtain a five-level component containing the target compound, further preparing 0.124g of the five-level component by HPLC high-pressure reversed phase, performing gradient elution by acetonitrile/water and the like in an elution system, wherein the peak-out time of the target compound is 15.22min, the detection wavelength is 228nm, and finally obtaining 86mg of the target compound;
(3) analyzing the structure of the target compound, finally determining the hydrogen spectrum and carbon spectrum information of the data through a nuclear magnetic resonance spectrogram (figures 11-12), comprehensively identifying the structure of the compound as shown in formula I by combining the hydrogen spectrum and carbon spectrum information with the correlation literature data Isolation and pharmaceutical Evaluation of Minor Cannabinoids from High-potential Cannabis sativa, wherein the nuclear magnetic resonance hydrogen spectrum and carbon spectrum data of the target compound are as follows:
1H NMR(850MHz,CDCl3)δ7.17–7.14(m,1H),7.06–7.03(m,1H),6.98(d,J＝8.2Hz,1H),6.45(s,1H),5.32(brs,1H),5.15(brs,2H),2.53(t,J＝7.7Hz,2H),2.31(s,3H),1.67–1.59(m,2H),1.40–1.30(m,4H),0.91(t,J＝6.6Hz,3H).
13C NMR(214MHz,CDCl3)δ153.99,152.40,146.48,132.06,131.91,131.50,117.19,116.48,108.34,106.99,35.99,31.65,30.77,22.69,20.59,14.17.
example 2
Identification of antitumor activity of phenolic compound ZKYY-037 shown in formula I
Medicine preparation: the compound of formula I, ZKYY-037, prepared in example 1.
(1) MTT colorimetric method for detecting influence of compound shown as formula I on tumor cell survival performance
Taking human liver cancer cells (HepG2) in a logarithmic growth phase, adjusting the cell concentration to 7000 cells per well by using a DMEM medium, inoculating 100 mu L of the DMEM medium per well into a 96-well plate, culturing in an incubator until the cells adhere to the wall, respectively preparing compound solutions shown in the formula I with the concentrations of 20ug/ml and 40ug/ml by using 100 mu L of DMSO as solvents, respectively adding the prepared compounds shown in the formula I with the concentrations of 20ug/ml and 40ug/ml into experimental groups for treatment, adding 100 mu L of DMSO into blank groups, and acting for 24 hours in the culture medium; detecting cell survival rate with MTT reagent by using 20ug/ml antitumor drug cisplatin (DDP) as control, repeating for 3 times, and averaging;
as shown in FIG. 1, the survival rate of the human liver cancer cell (HepG2) is lower with the increase of the concentration, namely, the inhibition effect of the compound ZKYY-037 shown in the formula I on the survival performance of the human liver cancer cell (HepG2) is stronger; when the concentration is 40ug/ml, the inhibition effect is only slightly worse than that of the antitumor drug DPP with the dosage of 20 ug/ml.
Taking human lung cancer cells (A549) in logarithmic growth phase, adjusting the cell concentration to 7000 cells per well by using a DMEM culture medium, inoculating 100 mu L of DMEM culture medium per well to a 96-well plate, culturing in an incubator until the cells adhere to the wall, respectively preparing compound solutions shown in formula I with the concentrations of 20ug/ml and 40ug/ml by using 100 mu L of DMSO as solvents, respectively adding the prepared compounds shown in formula I with the concentrations of 20ug/ml and 40ug/ml into experimental groups for treatment, adding 100 mu L of DMSO into blank groups, and acting for 24 hours under the culture medium; detecting cell survival rate with MTT reagent by using 20ug/ml antitumor drug cisplatin (DDP) as control, repeating for 3 times, and averaging;
as shown in fig. 2, the survival rate of human lung cancer cell (a549) is lower with the increase of the concentration, i.e., the inhibition effect of compound ZKYY-037 shown in formula I on the survival of human lung cancer cell (a549) is stronger; when the concentration is 40ug/ml, the inhibition effect is stronger than that of the antineoplastic drug cisplatin (DDP) with the dosage of 20 ug/ml.
(2) CKK8 cell proliferation toxicity detection method for detecting influence of compound shown in formula I on tumor cell survival performance
Taking human liver cancer cells (HepG2) in a logarithmic growth phase, adjusting the cell concentration to 7000 cells per well by using a DMEM medium, inoculating 100 mu L of the DMEM medium per well into a 96-well plate in an incubator, culturing in the incubator at 37 ℃ until the cells adhere to the wall, respectively preparing compound solutions shown in the formula I with the concentrations of 20ug/ml and 40ug/ml by using 100 mu L of DMSO as a solvent, respectively adding the prepared compounds shown in the formula I with the concentrations of 20ug/ml and 40ug/ml into an experimental group for treatment, adding 100 mu L of DMSO into a blank group, and acting for 24 hours in the culture medium; detecting cell survival rate with CCK8 kit with 20ug/ml antitumor drug cisplatin (DDP) as control, repeating for 3 times, and averaging;
as shown in FIG. 3, the survival rate of human liver cancer cells (HepG2) is lower with the increase of concentration, i.e. the inhibiting effect of the compound shown in formula I on the survival of human liver cancer cells (HepG2) is stronger; when the concentration is 40ug/ml, the inhibition effect is basically equivalent to that of the antitumor drug cisplatin (DDP) with the dosage of 20 ug/ml.
Taking human lung cancer cells (A549) in logarithmic growth phase, adjusting the cell concentration to 7000 cells per well by using a DMEM culture medium, inoculating 100 mu L of DMEM culture medium per well to a 96-well plate, culturing in an incubator until the cells adhere to the wall, respectively preparing compound solutions shown in formula I with the concentrations of 20ug/ml and 40ug/ml by using 100 mu L of DMSO as solvents, respectively adding the prepared compounds shown in formula I with the concentrations of 20ug/ml and 40ug/ml into experimental groups for treatment, adding 100 mu L of DMSO into blank groups, and acting for 24 hours under the culture medium; detecting cell survival rate with CCK8 kit with 20ug/ml antitumor drug cisplatin (DDP) as control, repeating for 3 times, and averaging;
as shown in fig. 4, the survival rate of human lung cancer cell (a549) is lower with the increase of the concentration, i.e., the compound of formula I has stronger inhibition effect on the survival of human lung cancer cell (a 549); when the concentration is 40ug/ml, the inhibition effect is stronger than that of the antineoplastic drug cisplatin (DDP) with the dosage of 20 ug/ml.
(3) Cell clone colony forming method for detecting influence of compound shown as formula I on proliferation performance of tumor cells
Taking human liver cancer cells (HepG2) in a logarithmic growth phase, digesting the cells into single cells, inoculating the single cells to a 6-well plate, adding 350 cells in each well, adding 3ML DMEM culture solution, culturing the cells to an adherent surface in an incubator, respectively preparing compound solutions shown in the formula I with the concentrations of 20ug/ML and 40ug/ML by taking 100 mu L DMSO as a solvent, respectively, adding the prepared compounds shown in the formula I with the concentrations of 20ug/ML and 40ug/ML into an experimental group, respectively, adding 100 mu L DMSO into a blank group, replacing fresh culture medium and medicament every 2-3 days, and continuously culturing for one week until macroscopic clones are formed; after each well is treated, a proper amount of 0.1% crystal violet is added for staining, then the staining solution is slowly washed away by running water, the cells are dried in the air, the clone number of the cells is counted, a picture is taken under a microscope (figure 5), and the cell colony forming rate is calculated. As shown in FIG. 6, the lower the colony formation rate of human hepatoma cells (HepG2) with increasing concentration, i.e., the stronger the inhibitory effect of the compound of formula I on the proliferation of human hepatoma cells (HepG 2).
Taking human lung cancer cells (A549) in a logarithmic growth phase, digesting the cells into single cells, inoculating the single cells to a 6-well plate, adding 350 cells in each well, adding 3ML DMEM culture solution, culturing the cells to an adherent surface in an incubator, respectively preparing compound solutions shown in formula I with the concentrations of 20ug/ML and 40ug/ML by taking 100 mu L DMSO as a solvent, respectively adding the prepared compounds shown in formula I with the concentrations of 20ug/ML and 40ug/ML into an experimental group, respectively treating the experimental group, adding 100 mu L DMSO into a blank group, replacing fresh culture medium and medicaments every 2-3 days, and continuously culturing for one week until macroscopic clones are formed; after each well is treated, a proper amount of 0.1% crystal violet is added for staining, then the staining solution is slowly washed away by running water, the cells are dried in the air, the clone number of the cells is counted, a picture is taken under a microscope (figure 7), and the cell colony forming rate is calculated. As shown in fig. 8, the lower the colony formation rate of human lung cancer cell (a549) with the increase in concentration, i.e., the stronger the inhibitory effect of the compound of formula I on the proliferation of human lung cancer cell (a 549).
(4) Detecting the influence of the compound shown as the formula I on the migration performance of tumor cells
Taking tumor cells in logarithmic growth phase as human liver cancer cells (HepG2), adjusting the cell concentration to 70000 cells/ML per well by using a DMEM culture medium, inoculating the DMEM culture medium with 2ML per well into a 12-well plate, culturing until the DMEM culture medium is fully paved at the bottom of the 12-well plate, and drawing a line from top to bottom by using culture wells of a sterile gun head; the experimental groups are respectively added with 100 mu L of culture medium to prepare DMSO dissolved compounds, the compounds shown in formula I with different concentrations of 20ug/ml and 40ug/ml are treated, the blank group is added with DMSO with the same volume, different time points are taken within 0-24 h for observation and photographing, and the cell migration condition is counted by calculating the area of a cell-free area in a scratch area.
As shown in FIG. 9, the compound of formula I can inhibit the migration ability of human liver cancer cells (HepG2), and the tumor cell migration rate decreases with increasing concentration, showing a decreasing relationship.
Taking tumor cells in logarithmic growth phase as human lung cancer cells (A549), adjusting the cell concentration to 70000 cells/ML by using a DMEM medium, inoculating 2ML of DMEM medium in each hole into a 12-hole plate, culturing until the DMEM medium is fully paved at the bottom of the 12-hole plate, and drawing a line from top to bottom by using culture holes of a sterile gun head; the experimental groups are respectively added with 100 mu L of culture medium to prepare DMSO dissolved compounds, the compounds shown in formula I with different concentrations of 20ug/ml and 40ug/ml are treated, the blank group is added with DMSO with the same volume, different time points are taken within 0-24 h for observation and photographing, and the cell migration condition is counted by calculating the area of a cell-free area in a scratch area.
The results are shown in fig. 10, the compound shown in formula I can inhibit the migration ability of human lung cancer cells (a549), and the tumor cell migration rate decreases with increasing concentration, showing a decreasing relationship.
It is noted that, herein, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or terminal that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or terminal. Without further limitation, an element defined by the phrases "comprising … …" or "comprising … …" does not exclude the presence of additional elements in a process, method, article, or terminal that comprises the element. Further, herein, "greater than," "less than," "more than," and the like are understood to exclude the present numbers; the terms "above", "below", "within" and the like are to be understood as including the number.
Although the embodiments have been described, once the basic inventive concept is obtained, other variations and modifications of these embodiments can be made by those skilled in the art, so that the above embodiments are only examples of the present invention, and not intended to limit the scope of the present invention, and all equivalent structures or equivalent processes using the contents of the present specification and drawings, or any other related technical fields, which are directly or indirectly applied thereto, are included in the scope of the present invention.
Claims (10)
1. A phenolic compound ZKYY-037 has a structure shown in formula I:
2. a process for the preparation of a compound of formula I according to claim 1, comprising the steps of:
(1) sequentially performing carbon dioxide supercritical extraction and ethanol extraction on inflorescences of the hemp plants to obtain crude extract;
(2) dissolving the obtained crude extract, and separating by normal phase silica gel column chromatography, macroporous adsorbent resin column chromatography, primary medium pressure normal phase silica gel column chromatography, secondary medium pressure normal phase silica gel column chromatography, tertiary medium pressure normal phase silica gel column chromatography, and high pressure reverse phase HPLC chromatography to obtain compound shown in formula I.
3. The method of claim 2, comprising any one or more of the following features: firstly, the supercritical carbon dioxide extraction conditions are as follows: pExtraction kettle＝20-30MPa，TExtraction kettle＝35-60℃；PSeparation kettle I＝8-11MPa，TSeparation kettle I＝35-65℃；PSeparation kettle II＝3-6MPa，TSeparation kettle II30-40 ℃; secondly, the usage amount of ethanol in the ethanol extraction is 15-25% of the weight of the hemp plant inflorescence, and the extraction time is 30-60 min; thirdly, fully dissolving the crude extract by using petroleum ether; fourthly, the normal phase silica gel column chromatography is carried out with n-hexane/ethyl acetate 98:2 as an eluent for isocratic elution; fifthly, performing gradient elution on the macroporous adsorption resin column by adopting a D101 macroporous adsorption resin column and using 30-100% ethanol/water as an eluent; sixthly, performing gradient elution on the first-stage medium-pressure normal-phase silica gel column chromatography by using dichloromethane/ethyl acetate as an eluent; seventhly, performing gradient elution on the secondary medium-pressure normal-phase silica gel column chromatography by using n-hexane/diethyl ether as an eluent; eighthly, carrying out gradient elution on the three-stage medium-pressure normal-phase silica gel column chromatography by using n-hexane/diethyl ether as an eluent; and ninthly, carrying out gradient elution by using acetonitrile/water solution as an eluent by the high-pressure reversed-phase HPLC chromatography.
4. Application of a compound ZKYY-037 shown in formula I in preparation of tumor cell proliferation inhibitor.
5. The tumor cell proliferation inhibitor medicine is characterized by comprising an active ingredient and pharmaceutically acceptable auxiliary materials, wherein the active ingredient comprises a compound shown in a formula I.
6. The use of a compound of formula I in the manufacture of a medicament for the treatment of a neoplastic disease.
7. An antitumor drug is characterized by comprising an active ingredient and pharmaceutically acceptable auxiliary materials, wherein the active ingredient comprises a compound shown as a formula I.
8. The use according to claim 4 or 6, wherein the neoplastic disease is liver cancer or lung cancer.
9. Antitumor drug according to claim 5 or 8, characterized in that it comprises an effective dose of the compound of formula I, preferably an effective dose of 572ng per dose.
10. The antitumor drug as claimed in claim 5 or 8, wherein the drug is an oral preparation or an injection preparation, and the oral preparation is one selected from dripping pills, tablets, capsules, granules or oral liquid; the injection preparation is selected from injection or powder injection.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010134894.9A CN111253222A (en) | 2020-03-02 | 2020-03-02 | Phenolic compound ZKYY-037 and preparation method and application thereof |
| CN2020101348949 | 2020-03-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112194572A true CN112194572A (en) | 2021-01-08 |
| CN112194572B CN112194572B (en) | 2023-01-10 |
Family
ID=70947574
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010134894.9A Pending CN111253222A (en) | 2020-03-02 | 2020-03-02 | Phenolic compound ZKYY-037 and preparation method and application thereof |
| CN202011176024.4A Active CN112194572B (en) | 2020-03-02 | 2020-10-29 | Phenolic compound ZKYY-037 and preparation method and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010134894.9A Pending CN111253222A (en) | 2020-03-02 | 2020-03-02 | Phenolic compound ZKYY-037 and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN111253222A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111574531A (en) * | 2020-05-15 | 2020-08-25 | 福建省中科生物股份有限公司 | Terpene phenolic compound NO85, and preparation method and application thereof |
| CN113087661A (en) * | 2021-03-24 | 2021-07-09 | 福建省中科生物股份有限公司 | 2 ', 6' -bipyridine substituted cannabidiol ether compound and preparation method and application thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111747827A (en) * | 2020-07-16 | 2020-10-09 | 南方科技大学 | Biphenyl triphenol compound and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1671639A (en) * | 2002-08-23 | 2005-09-21 | 康涅狄格大学 | Novel biphenyl and biphenyl-like cannabinoids |
| CN106518643A (en) * | 2016-10-14 | 2017-03-22 | 宁波大学 | Cyclopentene ketone compound and preparation method and application thereof |
| CN110105210A (en) * | 2019-05-17 | 2019-08-09 | 山东省肿瘤防治研究院（山东省肿瘤医院） | Thymol derivative and its preparation method and application |
-
2020
- 2020-03-02 CN CN202010134894.9A patent/CN111253222A/en active Pending
- 2020-10-29 CN CN202011176024.4A patent/CN112194572B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1671639A (en) * | 2002-08-23 | 2005-09-21 | 康涅狄格大学 | Novel biphenyl and biphenyl-like cannabinoids |
| CN106518643A (en) * | 2016-10-14 | 2017-03-22 | 宁波大学 | Cyclopentene ketone compound and preparation method and application thereof |
| CN110105210A (en) * | 2019-05-17 | 2019-08-09 | 山东省肿瘤防治研究院（山东省肿瘤医院） | Thymol derivative and its preparation method and application |
Non-Patent Citations (1)
| Title |
|---|
| RADWAN等: ""Isolation and characterization of new cannabis constituents from a high potency variety"", 《PLANTA MEDICA》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111574531A (en) * | 2020-05-15 | 2020-08-25 | 福建省中科生物股份有限公司 | Terpene phenolic compound NO85, and preparation method and application thereof |
| CN113087661A (en) * | 2021-03-24 | 2021-07-09 | 福建省中科生物股份有限公司 | 2 ', 6' -bipyridine substituted cannabidiol ether compound and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112194572B (en) | 2023-01-10 |
| CN111253222A (en) | 2020-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112190577B (en) | Application and preparation method of phenolic compound ZKYY-041 | |
| CN112194572B (en) | Phenolic compound ZKYY-037 and preparation method and application thereof | |
| CN112062744A (en) | Terpene phenolic compound ZKYY-057 and preparation method and application thereof | |
| CN111548332A (en) | Terpene phenolic compound NO95, and preparation method and application thereof | |
| CN112807301A (en) | Application of Cannabicol extracted from hemp plant in preparing antitumor drug | |
| CN111228246A (en) | Application and preparation method of terpene phenol | |
| CN111560001A (en) | Phenolic compound NO84, and preparation method and application thereof | |
| CN111574531A (en) | Terpene phenolic compound NO85, and preparation method and application thereof | |
| CN103191143B (en) | New application of cardiac glycoside compound | |
| CN107226820B (en) | A kind of trichophytin J with antitumor action and preparation method thereof and purposes | |
| CN111184710A (en) | Application and preparation method of cyclic phenol | |
| CN109608419A (en) | Diarylheptanoids extracted from pericarpium juglandis and its preparation method and application | |
| CN112079811A (en) | Phenolic compound ZKYY-013 and preparation method and application thereof | |
| CN105541858B (en) | Xanthone class compounds and preparation method thereof, composition and purposes | |
| CN111454153B (en) | Five ent-tisane diterpene compounds from euphorbia humifusa and preparation method and application thereof | |
| CN107118126B (en) | PPAP imine compound and preparation method thereof, pharmaceutical composition and purposes | |
| CN109734696A (en) | A kind of new diepoxy lignan compound and preparation method thereof | |
| CN112516134B (en) | Application of hydroxyl-containing compound in preparation of medicines | |
| CN111777512A (en) | Five diterpenoid compounds derived from euphorbia tirucalli as well as preparation method and application thereof | |
| CN104324043B (en) | A kind of purposes of cardiac glycoside compound | |
| CN110638822A (en) | Albizzia julibrissin glycoside compound for promoting endothelial cell proliferation and application thereof | |
| CN109879885B (en) | Novel compound and preparation method and application thereof | |
| CN114805382B (en) | Sesquiterpene chromone compound, separation thereof and application thereof in preparation of pancreatic cancer resisting drugs | |
| CN111808033B (en) | Preparation method and application of novel compound with antibacterial effect | |
| CN112300185B (en) | Alkaloid compound with reduced hepatotoxicity, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |